

# Neurology Grand Rounds

The University of Oklahoma Health Sciences Center

## "Neuropharmacology Clinical Pearls: Migraine"

Stephen Clayton, Jr., MD  
Assistant Professor  
Department of Neurology

February 19, 2019

8:00 am

Rainbolt Auditorium at Samis Education Center, 2<sup>nd</sup> Level  
The Children's Hospital, 1200 Children's Avenue

**Acknowledgement of Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

**Professional Practice Gap:** Throughout our medical careers, our focus tends to remain on clinical pathophysiology. Therefore, our understanding of disease processes are seldom viewed through the lens of "pre-clinical" basic sciences, except as early medical students – who lacked the clinical experience to tie everything together. This is especially true for the medications we utilize everyday: we have learned certain medications work for particular diseases yet often take it for granted why. This session will review some of those *whys* to hopefully help enrich clinical understanding.

**Learning Objectives:** Upon completion of this series, participants will improve their competence and performance by being able to:

1. List various neurotransmitters (including small molecules and neuropeptides) and receptors involved in migraine pathophysiology.
2. Describe the major biochemical effect of drugs or drug classes commonly used to treat migraine and primary headache disorders.
3. Recognize chemical structural similarities of certain medications used to treat migraine, either between each other or with neurotransmitters.



PLEASE POST



**Disclaimer Statement:**

Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Faculty and Presenter Disclosure:**

It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also discloses discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).

**Accreditation Statement:**

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Conflict Resolution Statement:**

The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

**Nondiscrimination Statement:**

The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, [bjm@ou.edu](mailto:bjm@ou.edu), or visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodation Statement:** For accommodation, please contact Brigitte Nettles at 271-4113.

## Disclosure & Resolution Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activities disclosure information.

Role	First Name	Last Name	Nature of Relevant Financial Relationship	
			Commercial Interest	What was received?
Course Director	Fahd	Sultan, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Course Contact	Brigitte	Nettles	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Planning Committee/ Moderator/Speaker	David Lee	Gordon, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Speaker	Stephen	Clayton, Jr., MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	

Dr. Clayton will be discussing off-label use of several medications as well as experimental drugs that have not been approved by the FDA.